**Participant flow**

n= number of eyes

**Baseline characteristics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Group | N | Mean | Std. Deviation | Std. Error | Levene Test for Homogeneity of Variances (P value) |
| Age | I | 15 | 72.73 | 8.89 | 2.29 | 0.04\* |
| II | 9 | 67.22 | 5.35 | 1.78 |
| CCh Grading | M | 10 | 6.40 | 1.77 | 0.56 | 0.37 |
| F | 14 | 5.64 | 2.20 | 0.58 |

M, male. F, female. N, number.

**Outcome measures**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 　 | Time/ Group | N | Mean | Minimum | Maximum |
| 　 |
| Conjunctivochalasis (CCh) grading　　　　　　　　 | 0 month | I | 29.00 | 5.90 | 2.00 | 9.00 |
| II | 17.00 | 6.18 | 2.00 | 9.00 |
| Total | 46.00 | 6.00 | 2.00 | 9.00 |
| 3 months | I | 29.00 | 1.38 | 0.00 | 5.00 |
| II | 17.00 | 0.00 | 0.00 | 0.00 |
| Total | 46.00 | 0.87 | 0.00 | 5.00 |
| 6 months | I | 29.00 | 1.52 | 0.00 | 4.00 |
| II | 17.00 | 0.06 | 0.00 | 1.00 |
| Total | 46.00 | 0.98 | 0.00 | 4.00 |
| Ocular Surface Disease Index (OSDI) score　　　　　　　　 | 0 month | I | 29.00 | 34.46 | 2.50 | 72.50 |
| II | 17.00 | 37.64 | 20.00 | 54.17 |
| Total | 46.00 | 35.63 | 2.50 | 72.50 |
| 3 months | I | 29.00 | 25.59 | 0.00 | 57.14 |
| II | 17.00 | 23.91 | 7.14 | 60.00 |
| Total | 46.00 | 24.97 | 0.00 | 60.00 |
| 6 months | I | 29.00 | 24.38 | 0.00 | 75.00 |
| II | 17.00 | 29.93 | 2.78 | 62.50 |
| Total | 46.00 | 26.43 | 0.00 | 75.00 |

**Adverse events**

There were no adverse events associated with this trial